Clinical Trials Logo

Filter by:
NCT ID: NCT03336216 Completed - Clinical trials for Advanced Pancreatic Cancer

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Start date: December 19, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

NCT ID: NCT03335761 Completed - Clinical trials for Urinary Urge Incontinence

InterStim® Amplitude Study

Start date: February 27, 2018
Phase: N/A
Study type: Interventional

This feasibility study will explore the effects of three different InterStim amplitude settings on overactive bladder symptoms (OAB).

NCT ID: NCT03335683 Completed - Clinical trials for Oral Soft Tissue Conditions

Phytotherapy Agent in Third Molar Surgery

Start date: January 7, 2016
Phase: Phase 4
Study type: Interventional

The aim of the present study was to evaluate the effect of a phytotherapy agent on clinical and inflammatory parameters, for the postoperative therapy of the impacted third molar surgery. The null hypothesis to invalidate was that, after the last follow-up, there were no variations between the phytotherapy agent and the placebo.

NCT ID: NCT03335488 Completed - Urea Cycle Disorder Clinical Trials

Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)

Start date: February 20, 2018
Phase: Phase 4
Study type: Interventional

This is a randomized, controlled, open-label parallel arm study to assess the safety, tolerability, pharmacokinetics and ammonia control, of RAVICTI® as compared to Sodium phenylbutyrate (NaPBA) in urea cycle disorder subjects not currently or previously chronically treated with phenylacetic acid (phenylacetate; PAA) prodrugs. The study design will include: 1) Baseline Period; 2) Initial Treatment Period; 3) a RAVICTI only Transition Period 4) a RAVICTI only Maintenance Period; and 5) a RAVICTI only Safety Extension Period. The study will run for approximately 25 weeks.

NCT ID: NCT03334630 Completed - Atrial Fibrillation Clinical Trials

DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation

DIAMOND-AF
Start date: November 6, 2017
Phase: N/A
Study type: Interventional

The purpose of the DIAMOND-AF study is to establish the safety and effectiveness of the DiamondTemp System for the treatment of drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation in patients.

NCT ID: NCT03334435 Completed - Atopic Dermatitis Clinical Trials

A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

BREEZE-AD3
Start date: March 28, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis. Participants were enrolled in this study from the originating studies (JAHL, JAHM, JAIY) or were directly enrolled in the open-label arm.

NCT ID: NCT03334396 Completed - Atopic Dermatitis Clinical Trials

A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

BREEZE-AD1
Start date: November 23, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of baricitinib as monotherapy in participants with moderate to severe atopic dermatitis.

NCT ID: NCT03334058 Completed - Pemphigus Vulgaris Clinical Trials

A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus

Start date: October 18, 2017
Phase: Phase 2
Study type: Interventional

The proposed study is an open-label, non-controlled, adaptive-design Phase II study to evaluate the safety, pharmacodynamics, pharmacokinetics, efficacy, and conditions of use (dosage, frequency of administration at maintenance) of ARGX-113 in patients with mild to moderate Pemphigus (Vulgaris or Foliaceus), either newly diagnosed or relapsing. The total study duration for each patient is less than 6 months. It consists of a Screening period, an Induction, a maintenance treatment period followed by a treatment-free Follow-up (FU) period.

NCT ID: NCT03332004 Completed - Clinical trials for Pelvic Endometriosis

Near-infrared Fluorescence Imaging as a Supportive Tool for Localisation of Deep Infiltrating Endometriosis During Laparoscopy

Start date: January 4, 2016
Phase: Phase 2
Study type: Interventional

The aim of the study is to establish a new and more accurate method to visualize the peritoneal changes caused by endometriosis using Indocyanine Green mediated fluorescence imaging. The hypothesis is that Indocyanine Green, a fluorescent dye that has wide applications throughout medicine in identifying vascularity of tissues and neovascularization, could facilitate the localization and excision of endometriotic lesions exploiting the hypervascularization due to the chronic inflammation

NCT ID: NCT03329846 Completed - Melanoma Clinical Trials

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Start date: November 30, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been treated